When compared with baseline, VLCD decreased plasma CETP concentration (−18.2%; P < 0.01). In addition, VLCD reduced plasma levels of total cholesterol (−13.1%; P < 0.001), TG (−45.1%; P < 0.001), phospholipid (−15.2%; P < 0.0001), LDL-cholesterol (−15.8%; P < 0.01), and apoB100 (−13.9%; P < 0.01). VLCD did not alter plasma HDL-cholesterol and HDL-phospholipids, but increased apoAI (+16.2%; P < 0.05) (Table 1). The change in body weight after 16 weeks of VLCD did not correlate with the change in either plasma TG (R2 = 0.0000; P = 0.9952), total cholesterol (R2 = 0.0471; P = 0.2769), phospholipid (R2 = 0.0305; P = 0.3837), LDL-cholesterol (R2 = 0.0320; P = 0.3717), HDL-cholesterol (R2 = 0.0086; P = 0.6460), or HDL-phospholipid (R2 = 0.0013; P = 0.8570).